You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 8,618,134

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,618,134

Title:	Method and composition for treating a serotonin receptor-mediated condition
Abstract:	A method and composition for treating serotonin receptor-mediated conditions.
Inventor(s):	Polymeropoulos; Mihael H. (Potomac, MD), Baroldi; Paolo (Potomac, MD), Wolfgang; Curt (Germantown, MD)
Assignee:	Vanda Pharmaceuticals Inc. (Washington, DC)
Application Number:	12/747,912
Patent Claims:	1. A method for antagonizing a 5-HT.sub.2A receptor in an animal suffering from a condition that is mediated by a 5-HT.sub.2A receptor, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof in a controlled release pharmaceutical dosage form. 2. The method of claim 1, wherein the 5-HT.sub.2A receptor is not located in the brain. 3. The method of claim 1, wherein the condition is selected from a group consisting of: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attacks, stable angina, unstable angina, thrombotic stroke, a secondary ischemic event, atrial fibrillation, thrombosis, restenosis, asthma, and a pathology associated with diabetes. 4. The method of claim 1, wherein the condition is a secondary ischemic event selected from a group consisting of: reversible ischemic neurological deficit and intermittent claudication. 5. The method of claim 3, wherein thrombosis comprises clot formation associated with at least one of the following: angioplasty, cardiac surgery, or atrial fibrillation. 6. The method of claim 1, wherein the condition is restenosis as a result of treatment with a medicated device. 7. The method of claim 6, wherein the medicated device is a medicated stent. 8. The method of claim 3, wherein the pathology associated with diabetes comprises at least one of the following: diabetic nephropathy or diabetic retinopathy. 9. The method of claim 1, further comprising: administering to the animal at least one antithrombotic agent. 10. The method of claim 9, wherein the antithrombotic agent is selected from a group consisting of: clopidogrel bisulfate, streptokinase, alteplase, aprotinin, aspirin, and warfarin. 11. The method of claim 1, wherein the 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof administered to the animal is between about 1 mg/day and about 500 mg/day. 12. The method of claim 11, wherein the amount is between about 5 mg/day and about 100 mg/day. 13. The method of claim 1, wherein the amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof administered to the animal is between about 0.01 mg/kg/day and about 10 mg/kg/day. 14. The method of claim 13, wherein the amount is between about 0.5 mg/kg/day and about 1.5 mg/kg/day. 15. The method of claim 1, wherein the animal is a human. 16. A method for antagonizing a 5-HT.sub.2A receptor in an animal suffering from a condition that is mediated by a 5-HT.sub.2A receptor, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof in a sustained release pharmaceutical dosage form. 17. The method of claim 1, wherein the controlled release pharmaceutical dosage form is a delayed release pharmaceutical dosage form. 18. The method of claim 1, wherein the controlled release pharmaceutical dosage form is a pulsatile release pharmaceutical dosage form. 19. A method for antagonizing a 5-HT.sub.2A receptor in an animal suffering from a condition that is mediated by a 5-HT.sub.2A receptor, the method comprising: internally administering to the animal an effective amount of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methox- y-benzoic acid or pharmaceutically-acceptable salt thereof.

Details for Patent 8,618,134

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	TRASYLOL	aprotinin	Injection	020304	12/29/1993	⤷ Try a Trial	2027-12-13
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987	⤷ Try a Trial	2027-12-13
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001	⤷ Try a Trial	2027-12-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.